Dr. Jordan Pober named the Ensign Professor

Dr. Jordan S. Pober, the newly appointed Ensign Professor of Immunobiology, is an expert on the biology and immunology of the vascular endothelium, whose studies may lead to new therapies for immune and inflammatory diseases and for improved outcomes in organ transplantation and tissue-engineered grafts.

Pober, who is the vice chair of the Department of Immunology for the Section of Human and Translational Immunology, is particularly interested in understanding the functions of vascular endothelial cells in inflammatory and immune responses, and, reciprocally, how inflammation and immunity affect vascular health and function.

Pober is also a professor of dermatology and of pathology.  He first came to Yale as a student in the University’s Medical Scientist Training Program, receiving his M.D. and Ph.D. degrees in 1977. He completed his first year of pathology residency at Yale-New Haven Hospital, then was a postdoctoral fellow at Harvard University from 1978 to 1980. He completed his pathology training at Brigham & Women’s Hospital and taught pathology at Harvard Medical School before returning to Yale in 1991 as a professor of pathology and immunobiology. He became a professor of dermatology in 1998.

Pober was named the director of the Molecular Cardiobiology Program at the Boyer Center for Molecular Medicine in 1991 and founded the Vascular Biology and Transplantation (VBT) Program in 1999. In 2007, he stepped down as the director of the VBT Program.

The Yale doctor and scientist has been honored as a Searle Scholar, an Established Investigator of the American Heart Association and a MERIT awardee of the National Heart, Lung and Blood Institute. He is the recipient of the Rous Whipple Award for 2011 from the American Society of Investigative Pathology. He has served as editor of Immunity and co-editor-in-chief of Laboratory Investigation. He has also served as president of the North American Vascular Biology Organization and is the co-founder and co-director of the Joint Yale-Cambridge University Biomedical Research Program.